[18F]-MFBG Versus [123I]-MIBG and [18F]-PE2I in PD vs. MSA and DLB vs. AD
Eligible age
18–85 yrs
Accepts
All genders
Locations
0 states
Healthy volunteers
Yes
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
Study goal: The goal of this prospective head to head comparison is to evaluate the effectiveness of \[18F\]-MFBG PET in assessing cardiac innervation, comparing it with \[123I\]-MIBG SPECT The study's primary focus is on distinguishing between Parkinson's disease (PD) and multiple system atrophy (MSA), as well as between dementia with Lewy bodies (DLB) and Alzheimer's disease (AD). Main questions: * Feasibility: How well can \[18F\]-MFBG PET detect changes in myocardial uptake in PD and DLB compared to the expected normal values in healthy individuals and AD and MSA-P patients? How well can it differentiate between these groups based on the detected changes? * Non-inferiority: Is \[18F\]-MFBG PET as accurate as \[123I\]-MIBG SPECT in distinguishing between PD and MSA-P, and between DLB and AD? Participant requirements: For the main study, participants will be required to visit the hospital for 3 or 4 appointments. During these visits, they will undergo a screening visit, MRI brain scan, a comprehensive neurological assessment, \[18F\]-PE2I PET, \[123I\]-MIBG SPECT, and \[18F\]-MFBG PET scans. Additionally, a separate dosimetry study will be conducted, involving healthy subjects who will visit the hospital for a screening visit and undergo \[18F\]-MFBG PET scans.
Sponsor: prof. dr. Koen Van Laere
You may qualify if…
- ✓ 1. Healthy Controls:
- ✓ Voluntary written informed consent.
- ✓ Use of highly effective methods of birth control.
- ✓ Age between 18 and 85 years.
- ✓ Good health based on medical history, physical examination, clinical laboratory tests, and urinalysis.
- ✓ No history or evidence of major neurological, internal, or psychiatric disorders.
- ✓ Normal structural MRI scan for subjects \< 60 years or minor lesions for subjects \>= 60 years.
- ✓ 2. Parkinson's Disease:
You may not qualify if…
- ✕ 1. Healthy controls:
- ✕ Major diseases that may interfere with the investigations.
- ✕ Evidence of cognitive impairment.
- ✕ History or evidence of psychiatric disease.
- ✕ Use of illicit drugs or history of drug or alcohol abuse.
- ✕ Chronic medication interfering with cardiac neuronal norepinephrine transporter (NET) or \[18F\]-FE-PE2I imaging.
- ✕ Exposure to ionizing radiation \> 1 mSv in other research studies within the last 12 months.
- ✕ Contraindication for MRI scanning.
Source: ClinicalTrials.gov · NCT06120049 · last updated 2025-02-06